FDA Clears Daré Bioscience’s IND for Phase 2 Trial of DARE-HPV, Aims to Treat Persistent High-Risk HPV

Event summary

  • FDA cleared Daré Bioscience’s IND application for DARE-HPV, enabling a Phase 2 clinical study for persistent high-risk HPV infection.
  • DARE-HPV is a proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert, designed as a non-surgical, self-administered therapy.
  • The Phase 2 study is supported by a $10 million contract from ARPA-H, with $6.5 million received to date.
  • Persistent high-risk HPV infection is linked to 99% of cervical cancer cases in the U.S., with no current FDA-approved pharmacologic treatments.

The big picture

Daré Bioscience’s FDA clearance for DARE-HPV marks a significant step in addressing the unmet need for treating persistent high-risk HPV infection, which currently lacks FDA-approved pharmacologic treatments. The Phase 2 trial, supported by ARPA-H funding, positions Daré to potentially redefine the treatment paradigm for cervical disease prevention, targeting the virus before it progresses to precancerous lesions. This development aligns with broader industry trends toward earlier intervention in women’s health, reducing reliance on surgical procedures that carry risks for fertility and preterm birth.

What we're watching

Clinical Trial Progress
The pace at which Daré Bioscience initiates and completes the Phase 2 study will determine the timeline for potential FDA approval of DARE-HPV.
Regulatory Pathway
Whether DARE-HPV can secure FDA approval as the first pharmacologic treatment for high-risk HPV infection, redefining cervical disease prevention.
Market Opportunity
The potential market impact of DARE-HPV, given the substantial unmet medical need for treating persistent high-risk HPV infection.

Related topics

Biotechnology